Radiation therapy, macrophages improve efficacy of nanoparticle-delivered cancer therapy stat : medicalxpress

These changes did not appear until 3 to 4 days after administration of radiation therapy and disappeared by day 11. Miller el al., "Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts," Science Translational Medicine (2017). Analysis of patient biopsy samples taken before and several days after radiation therapy for breast or cervical cancer revealed significant macrophage expansion in post-radiation samples, with the greatest increases in patients receiving the highest radiation dosage. Combining radiation therapy with cyclophosphamide - a DNA-damaging drug that enhances nanoparticle delivery to tumor cells through similar tumor-priming mechanisms - led to even greater nanoparticle uptake. Additional mouse studies showed that, beginning three days after radiation therapy, the uptake of nanoparticles but not of solvent-delivered drugs approximately doubled.




Radiation therapy is one of the most common treatments used to fight cancer, with an estimated 500,000 people each year receiving radiation therapy either alone or in combination with other treatments. The radiosensitivity index is based on the expression of different genes in a patient's tumor and has been validated in 9 different patient groups across different tumor types. However, different patients with similar tumor types, location, and stage may have different results after radiation therapy -- with improvement seen in one patient, but not in the other. Their discoveries are primed to place Moffitt at the forefront of a new era in personalized radiation therapy for head and neck cancer patients, as described in their recent article in the May issue of The Lancet Oncology. Integrated mathematical oncology uses experimental and clinical data to build models to predict a patient's response to radiation treatment.

Moffitt researchers hope to improve personalized radiation therapy for head and neck cancer patients

Radiation therapy is one of the most common treatments used to fight Cancer, with an estimated 500,000 people each year receiving radiation therapy either alone or in combination with other treatments. Physician scientists at Moffitt Cancer Center hope to change this approach to radiation therapy. Their discoveries are primed to place Moffitt at the forefront of a new era in personalized radiation therapy for head and neck cancer patients, as described in their recent article in the May issue of The Lancet Oncology. The radiosensitivity index is based on the expression of different genes in a patient's tumor and has been validated in 9 different patient groups across different tumor types. The researchers also believe that integrated mathematical oncology offers a unique approach to develop more personalized radiation therapy.


collected by :Lucy William

To follow all the new news about Health care